Symbols

TVRD

Tvardi Therapeutics·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TVRD

Tvardi Therapeutics, Inc.

A clinical stage biopharmaceutical company specializing in the development of small molecule inhibitors targeting STAT3

Industry

Pharmaceutical

Established Date

12/20/2017

Listing Date

01/31/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

tvarditherapeutics.com

Security Type

Common stock

Office address

3 Sugar Creek Ctr. Blvd., Suite 525, Sugar Land, Texas

Business

Introduction

Tvardi Therapeutics, Inc., incorporated on December 20, 2017, is a Delaware corporation headquartered in Houston, Texas. The Company is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies for STAT3 to treat fibrosis-driven diseases with significant unmet needs. Based on the pioneering work of its founders and a deep understanding of the transcription factor STAT3, the company has devised an innovative method to directly inhibit STAT3, a highly proven but historically non-drugable target. Using this expertise, the company is developing a pipeline of STAT3 inhibitors with differentiated mechanisms of action and convenient oral administration. The company's lead product candidate, TTI-101, is currently in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis, IPF and hepatocellular carcinoma, HCC.

Company Financials

EPS

TVRD has released its 2025 Q3 earnings. EPS was reported at -0.59, versus the expected -0.96, beating expectations. The chart below visualizes how TVRD has performed over recent quarters, highlighting trends in earnings surprises.